Analysis supporting treatment with Diamyd® published in peer-reviewed scientific journal

An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd[®],[ ]has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM).As communicated on 23 September 2021, treatment with Diamyd[®] in individuals recently diagnosed with type 1 diabetes carrying HLA DR3-DQ2 led to statistically significant positive treatment effects on longer time in the glycemic target range (